1020647 B.C. LTD.

Condensed Interim Financial Statements

For the nine months ended August 31, 2016

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, if an auditor has not performed a review of the condensed interim financial statements, they must be accompanied by a notice indicating that the condensed interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these condensed interim financial statements.

1020647 B.C. LTD.

Condensed Interim Statement of Financial Position
August 31, 2016 and November 30, 2015
(Expressed in Canadian dollars)
(Unaudited – Prepared by Management)

	August 31, 2016 $	November 30, 2015 $
Assets		
Current		
Cash	1,219	-
Other receivable	1,350	-
Prepaid expenses	4,725	
Note receivable (Note 10)	25,500	25,500
Total Assets	32,794	25,500
Liabilities		
Current		
Bank indebtedness	-	5
Accounts payable	1,489	1,019
Accrued liabilities	6,750	5,466
Loan payable (Note 10)	1,787	391
	10,026	6,881
Shareholders' Equity		
Capital stock (Note 5)	25,500	1
Share to be issued (Note 5)	10,000	25,499
Deficit	(12,732)	(6,881)
	22,768	18,619
Total Liabilities and Shareholders' Equity	32,794	25,495

Nature and Continuance of Operations (Note 1)
Commitment (Note 4)

Approved and authorized for issue by the Board of Directors on November 23, 2016:

"Matthew Reams"
Matthew Reams, Director

The accompanying notes are an integral part of these Condensed Interim Financial Statements

1020647 B.C. LTD.

Condensed Interim Statement of Loss and Comprehensive Loss
For the three and nine months ended August 31, 2016 and 2015
(Expressed in Canadian dollars)
(Unaudited – Prepared by Management)

	For the three months ended August 31,		For the nine months ended August 31,	
	2016	2015	2016	2015
	$	$	$	$
Expenses				
Bank charges and interest	28	19	104	37
Consulting fees	1,000	-	1,000	-
Office expense	44	-	44	-
Professional fees	2,025	-	4,125	-
Transfer agent and filing fees (recovery)	(2,927)	-	578	2,126
Net loss and total comprehensive loss for the period	(170)	(19)	(5,851)	(2,163)
Basic and diluted loss per common share	(0.00)	(19)	(0.01)	(2,163)
Weighted average number of common shares outstanding	1,250,917	1	727,807	1

The accompanying notes are an integral part of these Condensed Interim Financial Statements

1020647 B.C. LTD.
Condensed Interim Statement of Changes in Shareholders' Equity
For the nine month periods ended August 31, 2016 and 2015
(Expressed in Canadian dollars)
(Unaudited – Prepared by Management)

	Number of Shares \#	Share Capital $	Shares to be issued $	Deficit $	Total $
Share issued for cash on incorporation, December 1, 2014 Note (5)	1	1	-	-	1
Shares issued per plan of arrangement	-	-	25,499	-	25,499
Net loss and comprehensive loss for the period	-	-	-	(2,163)	(2,163)
Balance, August 31, 2015	1	1	25,499	(2,163)	23,337
Balance, November 30, 2015	1	1	25,499	(6,881)	18,619
Share cancelled and reissued	(1)	-	-	-	-
Shares issued per plan of arrangement (Note 5)	1,250,917	25,499	(25,499)	-	-
Share subscription received	-	-	10,000	-	10,000
Net loss and comprehensive loss for the period	-	-	-	(5,851)	(5,851)
Balance , August 31, 2016	1,250,917	25,500	10,000	(12,732)	22,768

The accompanying notes are an integral part of these Condensed Interim Financial Statements

1020647 B.C. LTD.
Condensed Interim Statement of Cash Flows
For the nine months ended August 31, 2016 and 2015
(Expressed in Canadian dollars)
(Unaudited – Prepared by Management)

	August 31, 2016	August 31, 2015
	$	$
Cash (used in) /provided by:		
Operating activities		
Net loss for the period	(5,851)	(2,163)
Change in non-cash working capital components		
Other receivable	(1,350)	-
Prepaid expenses	(4,725)	-
Accounts payable	470	519
Accrued liabilities	1,284	1,266
Net cash provided by (used in) operating activities	(10,172)	(378)
Financing activities		
Share subscription received	10,000	-
Loans payable	1,396	391
Net cash provided by financing activities	11,396	391
Change in cash	1,224	13
Bank indebtedness, beginning of the period	(5)	-
Cash, end of the period	1,219	13
Supplemental Disclosure of Cash Flow Information:		
Cash paid during the period:		
Interest expense	-	-
Income taxes	-	-
Non-cash transactions:		
Note receivable	-	(25,000)
Shares issued in exchange for note receivable	-	25,500
Shares to be issued	(25,499)	-
Share capital	25,499	-

1. NATURE AND CONTINUANCE OF OPERATIONS

1020647 BC Ltd. (the "Company") was incorporated on December 1, 2014 and, pursuant to a plan of arrangement (the "Arrangement") between the Company and Go Green Capital Corp. ("Go Green") dated December 4, 2014, it would acquire the letter of intent signed between Go Green and Euroex Ventures Ltd. ("Euroex") (the "Euroex LOI") and $25,500 in cash from Go Green as part of the arrangement agreement (the "Arrangement Agreement"), and would commence its business as a company to create a world-class sports injury and rehab center that offers stem cell-based therapies and protocols to target and repair a variety of sports injuries. As consideration for this asset, the Company would issue 5,073,667 common shares, multiplied by the Conversion Factor, as defined in the Arrangement Agreement, which shares would be distributed to the Go Green shareholders who hold Go Green shares on the share distribution record date. Go Green completed the Arrangement in May of 2015 and issued a note payable in the amount of $25,500 and assigned the Euroex LOI to the Company. The Company initiated the share distribution in April of 2015 and issued 1,250,917 common shares in May of 2015 to Go Green, which shares were re-distributed to the shareholders of Go Green as of record date of April 2, 2015. The Company, after acquiring a company from Euroex, will commence its business as a company to create and establish The Bahamas Centre for Sports Medicine ("**BCSM**") as a world-class sports injury and rehab center that offers stem cell-based therapies and protocols to target and repair a variety of sports injuries, based in Nassau, Bahamas. The objectives of the Company's management will be to raise equity funds to create a world-class sports injury and rehab center that offers stem cell-based therapies and protocols to target and repair a variety of sports injuries.

The head office and principal office of the Company is located at #13 – 7179 - 201st Street Langley BC V2Y 2Y9.

These unaudited condensed interim financial statements have been prepared on the basis of accounting principles applicable to a going concern which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation. The Company's continuing operations, as intended, and its financial success may be dependent upon the extent to which it can create a world-class sports injury and rehab center that offers stem cell-based therapies and protocols to target and repair a variety of sports injuries.

The commercialization of a world-class sports injury and rehab center that offers stem cell-based therapies and protocols to target and repair a variety of sports injuries may take many years to be in successful operation and the amount of resulting income, if any, is difficult to determine with any certainty. As a development stage company, the Company does not anticipate producing revenues for some time, other than from incidental revenue and the sales of marketable securities, if any. On August 31, 2016, the Company had not yet achieved profitable operations, a deficit of $12,732 and expects to incur further losses in the development of its business, all of which casts material uncertainty about the Company's ability to continue as a going concern.

These unaudited condensed interim financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

2. BASIS OF PRESENTATION

The Company was incorporated on December 1, 2014. These unaudited condensed interim financial statements are prepared in accordance and compliance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”). These unaudited condensed interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting.

These unaudited condensed interim financial statements are presented in Canadian dollars, which is the Company’s functional and reporting currency. These unaudited condensed interim financial statements are prepared on a historical cost basis except for financial instruments classified as fair value through profit or loss (“FVTPL”), which are stated at their fair value.

3. SIGNIFICANT ACCOUNTING POLICIES

The preparation of financial data is based on accounting principles and practices consistent with those used in the preparation of the audited financial statements as at November 30, 2015. The accompanying unaudited condensed interim financial statements should be read in conjunction with the Company’s audited financial statements for the year ended November 30, 2015.

<u>Accounting standards issued but not yet applied</u>

The following new standards and interpretations are not yet effective and have not been applied in preparing these financial statements. The Company is currently evaluating the potential impacts of these new standards and does not anticipate any material changes to the financial statements upon adoption of these new and revised accounting pronouncements.

- IFRS 9 – *Financial Instruments* (effective January 1, 2018) introduces new requirements for the classification and measurement of financial assets, and will replace IAS 39. IFRS 9 uses a single approach to determine whether a financial asset is measured at amortized cost or fair value, replacing the multiple classification options available in IAS 39.

- IFRS 15 – *Revenue from Contracts with Customers* (effective January 1, 2018) replaces the previous guidance on revenue recognition and provides a framework to determine when to recognize revenue and at what amount.

- IAS 1 – *Presentation of Financial Statements* (effective January 1, 2016) represents amendments outlining disclosure initiatives relating to materiality, ordering of the notes, subtotals, accounting policies and disaggregation with an aim of clarifying IAS 1 to address perceived impediments to preparers exercising their judgement in presenting their financial reports.

4. COMMITMENT

The Company has no commitment other than the Euroex LOI transferred from its former parent company, Go Green. As at the date of these financial statements, definitive agreement has not been entered into with Euroex.

5. CAPITAL STOCK

a. Authorized: unlimited Common shares without par value

b. Issued and Outstanding:

One common share was issued at $1 per common share on December 1, 2014 to Go Green.

As discussed in Note 1, the Company authorized to issue 1,250,917 common shares to Go Green and issuance of 1,250,917 shares was not completed until March 24, 2016. The aggregate fair value of these shares in the amount of $25,500 was based on the fair value estimates of assets transferred from Go Green to the Company. In May of 2015, Go Green issued a note receivable in the amount of $25,500 and assigned the Euroex LOI valued at $Nil to the Company.

Stock Options:

The Company has adopted an incentive stock option plan (the "Option Plan") which provides that the Board of Directors of the Company may from time to time, in its discretion, and in accordance with the applicable stock exchange's requirements, grant to directors, officers, employees and consultants to the Company, non-transferable options to purchase common shares. Pursuant to the Option Plan, the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares of the Company. Options granted under the Option Plan can have a maximum exercise term of 5 years from the date of grant. Vesting terms will be determined at the time of grant by the Board of Directors.

There were no stock options granted during the nine month period ended August 31, 2016.

6. EUROEX LETTER OF INTENT

On October 22, 2014, Go Green entered into a letter of intent with Euroex Ventures Ltd. with respect to a proposed transaction in which the Company will acquire a company from Euroex that will create and establish The Bahamas Center for Sports Medicine (BCSM) as a World Class Sports Injury and Rehab Center that offers Stem Cell based therapies and protocols to target and repair a variety of sports injuries.

7. CAPITAL DISCLOSURES

The Company's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders. The Company considers the items included in shareholders' equity and cash as capital. The Company manages the capital structure and makes adjustments to it in response to changes in economic conditions and the risk characteristics of the underlying assets. The Company's primary objective with respect to its capital management is to ensure that it has sufficient cash resources to create a world-class sports injury and rehab center that offers stem cell-based therapies and protocols to target and repair a variety of sports injuries. To secure the additional capital necessary to pursue these plans, the Company intends to raise additional funds through the equity or debt financing. The Company is not subject to any capital requirements imposed by a regulator.

8. FINANCIAL INSTRUMENTS

The Company's financial instruments consist of cash, other receivable, note receivable, bank indebtedness, accounts payable, accrued liabilities and loan payable. Cash and bank indebtedness are stated at fair value and classified within Level 1 of the fair value hierarchy. The fair values of other receivable, note receivable, accounts payable accrued liabilities and loan payable approximate their carrying values due to their short-term nature of these instruments.

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Strategic and operational risks are risks that arise if the Company fails to create a world-class sports injury and rehab center that offers stem cell-based therapies and protocols to target and repair a variety of sports injuries. These strategic opportunities or threats arise from a range of factors which might include changing economic and political circumstances and regulatory approvals and competitor actions. The risk is mitigated by consideration of other potential development opportunities and challenges which management may undertake.

The Company's credit risk was primarily attributable to bank balances. The Company limits its credit exposure on cash held in bank accounts firstly by holding its key transactional bank accounts with banks of international financial institutions.

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at August 31, 2016, the Company had cash balance of $1,219 and current liabilities of $10,026. All of the Company's financial liabilities have contractual maturities of less than 30 days, and are subject to normal trade terms. Management is considering different alternatives to secure adequate debt or equity financing to meet the Company short term and long term cash requirement.

8. FINANCIAL INSTRUMENTS (continued)

Interest risk is the risk that the fair value or future cash flows will fluctuate as a result of changes in market risk. The Company's sensitivity to interest rates is currently immaterial.

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company holds no financial instruments that are denominated in a currency other than Canadian dollar. Accrued liabilities are denominated in Canadian currency. Therefore, the Company's exposure to currency risk is minimal.

9. SEGMENTED INFORMATION

During the period ended August 31, 2016, the Company had one reportable operating segment, being to create a world-class sports injury and rehab center that offers stem cell-based therapies and protocols to target and repair a variety of sports injuries.

10. NOTE RECEIVABLE/LOAN PAYABLE

As at August 31, 2016, external parties have temporarily loaned $1,787 to the Company during the period ended August 31, 2016 in order to finance its short term operating expenses. These loans are unsecured, non-interest bearing and have no fixed terms of repayment.

The Company also received a note receivable in the amount of $25,500 from Go Green and, in exchange, issued 1,250,917 common shares to the shareholders of Go Green to complete the Arrangement. This note is non-interest bearing and has no fixed terms of repayment (Note 5).